YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype-Reference-Cited by-同舟云学术

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

Published:2021-03 Issue:3 Volume:16 Page:464-476
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Owonikoko Taofeek K.,Dwivedi Bhakti,Chen Zhengjia,Zhang Chao,Barwick Benjamin,Ernani Vinicius,Zhang Guojing,Gilbert-Ross Melissa,Carlisle Jennifer,Khuri Fadlo R.,Curran Walter J.,Ivanov Andrey A.,Fu Haian,Lonial Sagar,Ramalingam Suresh S.,Sun Shi-Yong,Waller Edmund K.,Sica Gabriel L.

Funder

National Institutes of Health

U.S. Department of Defense

Novartis

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N Engl J Med,2018

2. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019

3. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort;Ready;J Thorac Oncol,2020